Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FX1LB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,094
Award facts
- Contract value 100% obligated
- $41,093.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,093.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml autoinjector vials. This firm fixed-price delivery order, issued on November 5, 2025, with an ultimate completion date of November 28, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to support Department of Defense medical supply requirements globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity across diverse therapeutic categories including specialty biologics, oncology treatments, vaccines, and emergency medications. The company's single-award IDC under PPV-G GEN V, designated contract SPE2DR and awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. This contract structure positions the contractor to serve as a key pharmaceutical supplier for military healthcare facilities worldwide, fulfilling the specialized and recurring pharmaceutical needs of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DB26FX1LB?
SPE2DB26FX1LB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DB26FX1LB worth?
The government has obligated $41,094 on SPE2DB26FX1LB.
Is contract SPE2DB26FX1LB an order under another contract?
Yes. SPE2DB26FX1LB is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1LB competed?
The extent of competition for SPE2DB26FX1LB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award